• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

开发新型通用免疫受体用于抗原靶向：超越无限。

Development of a novel universal immune receptor for antigen targeting: To Infinity and beyond.

机构信息

Department of Pathology and Laboratory Medicine; University of Pennsylvania; Philadelphia, PA USA.

出版信息

Oncoimmunology. 2012 Aug 1;1(5):777-779. doi: 10.4161/onci.19730.

DOI:10.4161/onci.19730
PMID:22934280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3429592/
Abstract

Chimeric antigen receptors (CARs) possess fixed specificity for a single antigen and require empirical testing in T cells. To address this, we have developed a novel, adaptable immune receptor strategy that allows for the rapid generation and testing of T cells of nearly infinite antigen specificity.

摘要

嵌合抗原受体（CARs）对单一抗原具有固定的特异性，并且需要在 T 细胞中进行实证测试。为了解决这个问题，我们开发了一种新颖的、适应性强的免疫受体策略，能够快速生成和测试几乎具有无限抗原特异性的 T 细胞。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f3a/3429592/75563482a861/onci-1-777-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f3a/3429592/75563482a861/onci-1-777-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f3a/3429592/75563482a861/onci-1-777-g1.jpg

相似文献

1
Development of a novel universal immune receptor for antigen targeting: To Infinity and beyond.开发新型通用免疫受体用于抗原靶向：超越无限。
Oncoimmunology. 2012 Aug 1;1(5):777-779. doi: 10.4161/onci.19730.
2
A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.通过使用新型 T 细胞抗原受体的癌症过继免疫疗法的通用策略。
Cancer Res. 2012 Apr 1;72(7):1844-52. doi: 10.1158/0008-5472.CAN-11-3890. Epub 2012 Feb 7.
3
The Emergence of Universal Immune Receptor T Cell Therapy for Cancer.癌症通用免疫受体T细胞疗法的出现。
Front Oncol. 2019 Mar 26;9:176. doi: 10.3389/fonc.2019.00176. eCollection 2019.
4
Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors.设计的锚蛋白重复蛋白是嵌合抗原受体的有效靶向元件。
J Immunother Cancer. 2015 Dec 15;3:55. doi: 10.1186/s40425-015-0099-4. eCollection 2015.
5
Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor.通过将靶向配体共价连接到通用免疫受体来定量控制基因工程 T 细胞的活性。
J Am Chem Soc. 2020 Apr 8;142(14):6554-6568. doi: 10.1021/jacs.9b11622. Epub 2020 Mar 30.
6
The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞设计中的不断发展的蛋白质工程。
Int J Mol Sci. 2019 Dec 27;21(1):204. doi: 10.3390/ijms21010204.
7
Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells.系统性检测和同种异体抗原特异性嵌合抗原受体在调节性 T 细胞中的特异性作图。
JCI Insight. 2019 Mar 21;4(6). doi: 10.1172/jci.insight.123672.
8
T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.表达VHH导向的寡克隆嵌合HER2抗原受体的T细胞：迈向肿瘤导向的寡克隆T细胞疗法。
Biochim Biophys Acta. 2014 Jan;1840(1):378-86. doi: 10.1016/j.bbagen.2013.09.029. Epub 2013 Sep 27.
9
Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.嵌合抗原受体工程化先天免疫细胞在癌症免疫治疗中的应用。
Sci China Life Sci. 2019 May;62(5):633-639. doi: 10.1007/s11427-018-9451-0. Epub 2019 Feb 15.
10
The promise and potential pitfalls of chimeric antigen receptors.嵌合抗原受体的前景与潜在风险。
Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25.

引用本文的文献

1
Universal CAR 2.0 to overcome current limitations in CAR therapy.通用 CAR 2.0 克服 CAR 疗法当前的局限性。
Front Immunol. 2024 Jun 19;15:1383894. doi: 10.3389/fimmu.2024.1383894. eCollection 2024.
2
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.调整 CAR：修饰嵌合抗原受体 (CAR) T 细胞活性以提高安全性、疗效和灵活性的最新进展。
J Transl Med. 2023 Mar 15;21(1):197. doi: 10.1186/s12967-023-04041-6.
3
Engineering switchable and programmable universal CARs for CAR T therapy.

本文引用的文献

1
A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.通过使用新型 T 细胞抗原受体的癌症过继免疫疗法的通用策略。
Cancer Res. 2012 Apr 1;72(7):1844-52. doi: 10.1158/0008-5472.CAN-11-3890. Epub 2012 Feb 7.
2
Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.经嵌合型抗间皮素人源化受体转导的原代人淋巴细胞的抗肿瘤活性重定向。
Mol Ther. 2012 Mar;20(3):633-43. doi: 10.1038/mt.2011.256. Epub 2011 Nov 29.
3
Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers.
工程化可切换和可编程通用嵌合抗原受体用于 CAR-T 疗法。
J Hematol Oncol. 2019 Jul 4;12(1):69. doi: 10.1186/s13045-019-0763-0.
4
Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies.实体瘤的嵌合抗原受体T细胞疗法：现状、障碍与未来策略
Cancers (Basel). 2019 Feb 6;11(2):191. doi: 10.3390/cancers11020191.
5
The development of CAR design for tumor CAR-T cell therapy.用于肿瘤CAR-T细胞疗法的CAR设计的发展
Oncotarget. 2018 Jan 12;9(17):13991-14004. doi: 10.18632/oncotarget.24179. eCollection 2018 Mar 2.
6
mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting.用于通用肿瘤靶向的mSA2亲和力增强的生物素结合嵌合抗原受体T细胞。
Oncoimmunology. 2017 Oct 26;7(1):e1368604. doi: 10.1080/2162402X.2017.1368604. eCollection 2017.
7
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.开关介导的嵌合抗原受体T细胞（CAR-T细胞）对B细胞恶性肿瘤的激活与重定向
Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E459-68. doi: 10.1073/pnas.1524155113. Epub 2016 Jan 12.
8
Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging.用于EGFRvIII表达型胶质瘤过继性免疫治疗的重定向人抗生物素蛋白CAR T细胞及其通过光学成像的评估
Oncotarget. 2015 Sep 15;6(27):23735-47. doi: 10.18632/oncotarget.4362.
9
Engineered T cells for cancer treatment.肿瘤治疗用工程化 T 细胞。
Cytotherapy. 2014 Jun;16(6):713-33. doi: 10.1016/j.jcyt.2013.10.002. Epub 2013 Nov 13.
用于B细胞恶性肿瘤和实体癌的个性化细胞转移免疫疗法。
Mol Ther. 2011 Nov;19(11):1928-30. doi: 10.1038/mt.2011.223.
4
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.嵌合抗原受体修饰的 T 细胞治疗慢性淋巴细胞白血病。
N Engl J Med. 2011 Aug 25;365(8):725-33. doi: 10.1056/NEJMoa1103849. Epub 2011 Aug 10.
5
Redirected tumor-specific allogeneic T cells for universal treatment of cancer.定向肿瘤特异性同种异体 T 细胞用于癌症的通用治疗。
Blood. 2011 Jul 28;118(4):975-83. doi: 10.1182/blood-2011-02-334284. Epub 2011 Jun 7.
6
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.自体 T 细胞经基因工程改造后识别 CD19，用于治疗患者，可消除 B 细胞系细胞并使淋巴瘤消退。
Blood. 2010 Nov 18;116(20):4099-102. doi: 10.1182/blood-2010-04-281931. Epub 2010 Jul 28.
7
Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment.可预防CA125/间皮素依赖性细胞黏附的抗间皮素双特异性抗体的研发及体外验证
Cancer Lett. 2007 Oct 8;255(2):263-74. doi: 10.1016/j.canlet.2007.04.012. Epub 2007 Jun 7.
8
Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells.使用CD3x19双特异性抗体对B细胞淋巴瘤进行免疫治疗：通过CD28共刺激可防止抗体靶向的细胞毒性T细胞的“否决”性凋亡。
Blood. 1998 Dec 15;92(12):4750-7.
9
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.通过由抗体结合域以及免疫球蛋白和T细胞受体的γ或ζ亚基组成的嵌合单链对细胞毒性淋巴细胞进行特异性激活和靶向。
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4. doi: 10.1073/pnas.90.2.720.
10
Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity.B7:CD28 通路在移植耐受和肿瘤免疫中的关键作用。
Blood. 1994 Nov 15;84(10):3261-82.